To evaluate the therapeutic efficacy of NK92-Neo2/15-OX40L expanded NK cells in vivo, killing assays were performed on HepG2 (liver cancer), A427 (lung cancer) and CAVO3 (ovarian cancer) derived xenograft models. This evidence concerns the gene TNFSF4 and ovarian cancer.